Skip to main content
Publications
Cruz Rivera S, Aiyegbusi OL, Ives J, Draper H, Mercieca-Bebber R, Ells C, Hunn A, Scott JA, Fernandez CV, Dickens AP, Anderson N, Bhatnagar V, Bottomley A, Campbell L, Collett C, Collis P, Craig K, Davies H, Golub R, Gosden L, Gnanasakthy A, Haf Davies E, von Hildebrand M, Lord JM, Mahendraratnam N, Miyaji T, Morel T, Monteiro J, Zwisler AO, Peipert JD, Roydhouse J, Stover AM, Wilson R, Yap C, Calvert MJ. Ethical considerations for the inclusion of patient-reported outcomes in clinical research: the PRO ethics guidelines. JAMA. 2022 May 17;327(19):1910-9. doi: 10.1001/jama.2022.6421
Mazurek M, Halperin JL, Huisman MV, Diener HC, Dubner SJ, Ma CS, Rothman KJ, Healey JS, Teutsch C, Paquette M, Franca LR, Lu S, Bartels DB, Lip GYH. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Europace. 2020 Jan 1;22(1):47-57. doi: 10.1093/europace/euz278
Hoffman E, Mladsi DM, Cryer B, Hopkins W, Brater DC, Parikh R, Goyal R, Castellsague J, Stafkey-Mailey D, Young C. Dose-related risks of cardiovascular, gastrointestinal, and renal adverse events associated with meloxicam among patients with osteoarthritis: an observational study using US claims data. Poster presented at the 2016 ACR/ARHP Annual Meeting; November 15, 2016. Washington, DC. [abstract] Arthritis Rheumatol. 2016 Sep 28; 68(Suppl 10).
Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ, Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GY. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) phase I cohort. Europace. 2016 Sep;18(9):1308-18. doi: 10.1093/europace/euw073
Rodes-Cabau J, Horlick E, Ibrahim R, Cheema AN, Labinaz M, Nadeem N, Osten M, Cote M, Marsal JR, Rivest D, Marrero A, Houde C. Effect of clopidogrel and aspirin vs aspirin alone on migraine headaches after transcatheter atrial septal defect closure: the CANOA randomized clinical trial. JAMA. 2015 Nov 24;314(20):2147-54. doi: 10.1001/jama.2015.13919
Gossec L, Kvien TK, Conaghan PG, Ostergaard M, Canete JD, Gaillez C, Mpofu S, Sherif B, Jugl S. Relationship between improvements in fatigue and signs & symptoms of active psoriatic: arthritis a sub-analysis of a phase 3 study with secukinumab. Poster presented at the 2015 ACR/ARHP Annual Meeting; November 10, 2015. San Francisco, CA. [abstract] Arthritis Rheumatol. 2015 Sep 29; 67(Suppl 10).
Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001 Dec 19;286(23):2947-55.
Helliwell PS, Doward L, Whalley D, Tennant A, McKenna S, Reynolds S, Kay L, Spoorenberg A, van der Heijde Leeds D. Psychometric and scaling properties of a new quality of life instrument specific to ankylosing spondylitis (AS). Poster presented at the 1999 ACR/ARHP Annual Scientific Meeting; November 14, 1999. Boston, MA. [abstract] Arthritis Rheumatol. 1999 Sep; 42(S9):s72.